Gastrointestinal Guidelines for Adults
Colorectal Cancer Screening
All average-risk adults should begin colorectal cancer screening at age 45 and continue through age 75 if life expectancy exceeds 10 years 1, 2, 3. This represents the current consensus across major professional societies including the U.S. Multi-Society Task Force, American Cancer Society, and American College of Gastroenterology.
Starting Age
- Age 45-49: Screening is recommended (Grade B evidence from USPSTF), though the strength of recommendation is qualified as the evidence is stronger for age 50+ 1
- Age 50-75: Strong recommendation with high-quality evidence 1, 3
Stopping Age Algorithm
- Age 75 or less with life expectancy <10 years: Stop screening 1
- Age 76-85: Individualize based on:
- Prior screening history (those never screened may benefit up to age 85)
- Overall health status and comorbidities
- Patient preferences
- If previously well-screened with negative results, stopping at 75 is reasonable 1
- Age 86+: Do NOT offer screening—mortality risk and colonoscopy complications outweigh benefits 1
Screening Test Options
Preferred stool-based tests (offer multiple options to improve participation) 2:
- High-sensitivity fecal immunochemical test (FIT) or guaiac-based fecal occult blood test: annually
- Next-generation multitarget stool DNA (mt-sDNA) test: every 3 years
- Multitarget stool RNA (mt-sRNA) test: every 3 years
Colonoscopy: Remains the one-step diagnostic and therapeutic option 3, 4
Blood-based cell-free DNA tests: Should ONLY be recommended for patients who decline or do not complete preferred screening tests, as they demonstrate lower sensitivity for advanced precancerous lesions and stage I cancers 2
Critical Caveat
Any positive non-colonoscopy screening test requires colonoscopy follow-up within 6 months to complete the screening process 2. This is non-negotiable for screening effectiveness.
Gastroesophageal Reflux Disease (GERD) Treatment
The American College of Gastroenterology guidelines on GERD management show 94-98% adherence among primary care physicians 5, indicating well-established, evidence-based protocols are in place. While specific treatment algorithms weren't detailed in the provided evidence, the high adherence rate suggests clear, actionable guidelines exist in clinical practice.
Helicobacter pylori-Associated Peptic Ulcer Disease
For treatment-naive patients with H. pylori infection, use bismuth quadruple therapy (BQT) for 14 days when antibiotic susceptibility is unknown 6. This is the preferred first-line regimen.
First-Line Treatment Options (when susceptibility unknown)
- Bismuth quadruple therapy for 14 days (preferred) 6
- Rifabutin triple therapy for 14 days (alternative if no penicillin allergy) 6
- Potassium-competitive acid blocker dual therapy for 14 days (alternative if no penicillin allergy) 6
Treatment-Experienced Patients (Persistent Infection)
- If NOT previously treated with optimized BQT: Use optimized BQT for 14 days 6
- If previously treated with optimized BQT: Use rifabutin triple therapy for 14 days 6
- Clarithromycin or levofloxacin salvage regimens: ONLY use if antibiotic susceptibility is confirmed 6
Who to Test for H. pylori
Based on physician practice patterns 5:
- Suspected peptic ulcer disease (85% of physicians test)
- Unexplained iron deficiency anemia (61% test)
- First-degree relatives of gastric cancer patients (46% test)
Testing Method
- Urea breath test is the preferred diagnostic method for young patients with dyspepsia without alarm symptoms (74% of physicians use this) 5
- Refer to gastroenterology specialist if alarm symptoms present (81% adherence) 5
Post-Treatment
Universal test-of-cure is required for all treated patients 6
Practice Gap Alert
Only 50% of primary care physicians report using professional guidelines for H. pylori management 5, indicating significant room for improvement in guideline adherence compared to GERD management.
Irritable Bowel Syndrome (IBS) Management
The provided evidence does not contain specific guidelines for IBS management. This topic requires separate guideline consultation.
Inflammatory Bowel Disease (IBD) Therapy and Monitoring
Use a multimodal approach to monitor remission in ulcerative colitis patients, combining clinical indices, laboratory markers, and endoscopic assessment 7.
Monitoring Strategy for Ulcerative Colitis Remission
Required assessments 7:
- Clinical activity index (partial Mayo or Simple Clinical Colitis Activity Index)
- Hemoglobin
- C-reactive protein (CRP)
- Fecal calprotectin OR intestinal ultrasound (if available)
- Colonoscopy or sigmoidoscopy with histology (ideally)
Fecal Calprotectin Thresholds and Actions 7
- <100 μg/g: Target associated with lower probability of clinical relapse
- 100-200 μg/g: In otherwise well patients, repeat testing within a reasonable timeframe; further increase suggests treatment complications
- >200 μg/g: TRIGGERS mandatory discussion about lower GI endoscopy
- <250 μg/g: Associated with endoscopic and histological remission; protective against hospitalization or colectomy
Monitoring Frequency
Depends on:
- Current therapy
- Duration of remission
- Local resource availability 7
Colorectal Cancer Surveillance in IBD 7, 8
- First surveillance colonoscopy: 8 years after symptom onset for any colonic IBD
- Pancolitis patients: Regular ongoing colonoscopy (specific intervals per BSG guidance)
- Timing: Surveillance should be performed when patient is in remission 7
Additional Monitoring Considerations 7
- Confirm adherence to cancer surveillance programs
- Evaluate extraintestinal manifestations
- Assess vaccination status
- Monitor for therapy complications
Treatment Targets Evolution
The field has moved from traditional clinical remission to include endoscopic and laboratory-assessed remission, with mucosal healing associated with long-term clinical remission 7. However, colonoscopy confirmation is expensive and less patient-acceptable than blood/stool biomarkers or intestinal ultrasound.